Integrating pharmacogenetic information and clinical decision support into the electronic health record

被引:51
作者
Goldspiel, Barry R. [1 ]
Flegel, Willy A. [2 ]
DiPatrizio, Gary [3 ]
Sissung, Tristan [4 ]
Adams, Sharon D. [2 ]
Penzak, Scott R. [1 ]
Biesecker, Leslie G. [5 ]
Fleisher, Thomas A. [6 ]
Patel, Jharana J. [1 ]
Herion, David [3 ]
Figg, William D. [4 ]
Lertora, Juan J. L. [7 ]
McKeeby, Jon W. [3 ]
机构
[1] NIH, Ctr Clin, Dept Pharm, Bethesda, MD 20892 USA
[2] NIH, Ctr Clin, Dept Transfus Med, Bethesda, MD 20892 USA
[3] NIH, Ctr Clin, Dept Clin Res Informat, Bethesda, MD 20892 USA
[4] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
[5] NHGRI, Genet Dis Res Branch, Bethesda, MD 20892 USA
[6] NIH, Ctr Clin, Dept Lab Med, Bethesda, MD 20892 USA
[7] NIH, Ctr Clin, Clin Pharmacol Program, Bethesda, MD 20892 USA
关键词
IMPLEMENTATION CONSORTIUM GUIDELINES; THIOPURINE METHYLTRANSFERASE GENOTYPE; HLA-B GENOTYPE; HYPERSENSITIVITY; MEDICINE;
D O I
10.1136/amiajnl-2013-001873
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Pharmacogenetics (PG) examines gene variations for drug disposition, response, or toxicity. At the National Institutes of Health Clinical Center (NIH CC), a multidepartment Pharmacogenetics Testing Implementation Committee (PGTIC) was established to develop clinical decision support (CDS) algorithms for abacavir, carbamazepine, and allopurinol, medications for which human leukocyte antigen (HLA) variants predict severe hypersensitivity reactions. Providing PG CDS in the electronic health record (EHR) during order entry could prevent adverse drug events. Medical Logic Module (MLM) programming was used to implement PG CDS in our EHR. The MLM checks to see if an HLA sequence-based gene test is ordered. A message regarding test status (result present, absent, pending, or test not ordered) is displayed on the order form, and the MLM determines if the prescriber can place the order, place it but require an over-ride reason, or be blocked from placing the order. Since implementation, more than 725 medication orders have been placed for over 230 patients by 154 different prescribers for the three drugs included in our PG program. Prescribers commonly used an over-ride reason when placing the order mainly because patients had been receiving the drug without reaction before implementation of the CDS program. Successful incorporation of PG CDS into the NIH CC EHR required a coordinated, interdisciplinary effort to ensure smooth activation and a positive effect on patient care. Prescribers have adapted to using the CDS and have ordered PG testing as a direct result of the implementation.
引用
收藏
页码:522 / 528
页数:7
相关论文
共 25 条
[1]   HLA class I and II genotype of the NCI-60 cell lines [J].
Adams, S ;
Robbins, FM ;
Chen, D ;
Wagage, D ;
Holbeck, SL ;
Morse, HC ;
Stroncek, D ;
Marincola, FM .
JOURNAL OF TRANSLATIONAL MEDICINE, 2005, 3 (1)
[2]   Development and use of active clinical decision support for preemptive pharmacogenomics [J].
Bell, Gillian C. ;
Crews, Kristine R. ;
Wilkinson, Mark R. ;
Haidar, Cyrine E. ;
Hicks, J. Kevin ;
Baker, Donald K. ;
Kornegay, Nancy M. ;
Yang, Wenjian ;
Cross, Shane J. ;
Howard, Scott C. ;
Freimuth, Robert R. ;
Evans, William E. ;
Broeckel, Ulrich ;
Relling, Mary V. ;
Hoffman, James M. .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2014, 21 (E1) :E93-E99
[3]   Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan [J].
Chen, Pei ;
Lin, Juei-Jueng ;
Lu, Chin-Song ;
Ong, Cheung-Ter ;
Hsieh, Peiyuan F. ;
Yang, Chih-Chao ;
Tai, Chih-Ta ;
Wu, Shey-Lin ;
Lu, Cheng-Hsien ;
Hsu, Yung-Chu ;
Yu, Hsiang-Yu ;
Ro, Long-Sun ;
Lu, Chung-Ta ;
Chu, Chun-Che ;
Tsai, Jing-Jane ;
Su, Yu-Hsiang ;
Lan, Sheng-Hsing ;
Sung, Sheng-Feng ;
Lin, Shu-Yi ;
Chuang, Hui-Ping ;
Huang, Li-Chen ;
Chen, Ying-Ju ;
Tsai, Pei-Joung ;
Liao, Hung-Ting ;
Lin, Yu-Hsuan ;
Chen, Chien-Hsiun ;
Chung, Wen-Hung ;
Hung, Shuen-Iu ;
Wu, Jer-Yuarn ;
Chang, Chi-Feng ;
Chen, Luke ;
Chen, Yuan-Tsong ;
Shen, Chen-Yang .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (12) :1126-1133
[4]   Pharmacogenomics and Individualized Medicine: Translating Science Into Practice [J].
Crews, K. R. ;
Hicks, J. K. ;
Pui, C-H ;
Relling, M. V. ;
Evans, W. E. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (04) :467-475
[5]   The Path to Personalized Medicine [J].
Hamburg, Margaret A. ;
Collins, Francis S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (04) :301-304
[6]   Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing [J].
Hershfield, M. S. ;
Callaghan, J. T. ;
Tassaneeyakul, W. ;
Mushiroda, T. ;
Thorn, C. F. ;
Klein, T. E. ;
Lee, M. T. M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (02) :153-158
[7]   A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record [J].
Hicks, J. K. ;
Crews, K. R. ;
Hoffman, J. M. ;
Kornegay, N. M. ;
Wilkinson, M. R. ;
Lorier, R. ;
Stoddard, A. ;
Yang, W. ;
Smith, C. ;
Fernandez, C. A. ;
Cross, S. J. ;
Haidar, C. ;
Baker, D. K. ;
Howard, S. C. ;
Evans, W. E. ;
Broeckel, U. ;
Relling, M. V. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (05) :563-566
[8]   Abacavir hypersensitivity reaction: an update [J].
Hughes, Christine A. ;
Foisy, Michelle M. ;
Dewhurst, Norman ;
Higgins, Niamh ;
Robinson, Linda ;
Kelly, Deborah V. ;
Lechelt, Kelly E. .
ANNALS OF PHARMACOTHERAPY, 2008, 42 (03) :387-396
[9]   To Replicate or Not to Replicate: The Case of Pharmacogenetic Studies Have Pharmacogenomics Failed, or Do They Just Need Larger-Scale Evidence and More Replication? [J].
Ioannidis, John P. A. .
CIRCULATION-CARDIOVASCULAR GENETICS, 2013, 6 (04) :413-418
[10]   Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing [J].
Leckband, S. G. ;
Kelsoe, J. R. ;
Dunnenberger, H. M. ;
George, A. L., Jr. ;
Tran, E. ;
Berger, R. ;
Mueller, D. J. ;
Whirl-Carrillo, M. ;
Caudle, K. E. ;
Pirmohamed, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (03) :324-328